Cetuximab resistance induced by hepatocyte growth factor is overcome by MET inhibition in KRAS, NRAS, and BRAF wild-type colorectal cancers.
Sang-A KimHyejoo ParkKui-Jin KimJi-Won KimJi Hea SungMilang NamJu Hyun LeeEun Hee JungKoung Jin SuhJi Yun LeeSe Hyun KimJeong-Ok LeeJin Won KimYu Jung KimJee Hyun KimSoo-Mee BangJong Seok LeeKeun-Wook LeePublished in: Journal of cancer research and clinical oncology (2021)
Patients with mCRC receiving cetuximab + FOLFIRI who presented with high plasma HGF levels had significantly worse PFS and OS. Cetuximab resistance induced by HGF was mediated by AKT and ERK activation and overcome by MET inhibition in vitro.